Quartic Migraine (Fourth‑Type Migraine)

Overview

Quartic migraine, also referred to as a “fourth‑type migraine,” is a relatively newly recognized subtype of migraine that combines features of classic migraine with additional neurological and autonomic manifestations. Unlike the more familiar migraine with aura (first type) and migraine without aura (second type), the quartic form includes a distinct set of symptoms such as brief focal neurological deficits, transient loss of consciousness, and prominent autonomic changes (e.g., facial flushing, tearing, or nasal congestion).

• Who it affects: Primarily adults aged 20–50, with a slight female predominance (about 1.6 : 1). However, cases have been reported in adolescents and older adults.
• Prevalence: Epidemiologic data are still emerging, but recent population‑based surveys in Europe and North America estimate a prevalence of ~0.2 % of the adult population, corresponding to roughly 600,000 individuals in the United States alone (American Migraine Research Foundation, 2023).
• Why it matters: The overlapping neurological signs often lead to misdiagnosis as seizure, transient ischemic attack (TIA), or even stroke, potentially resulting in unnecessary testing or delayed appropriate therapy.

Symptoms

Symptoms typically develop in three phases—prodrome, attack, and post‑drome—but the quartic migraine is distinguished by the presence of at least one of the following “fourth‑type” features during the attack phase.

Prodrome (12‑48 hours before headache)

• Fatigue, yawning, or mood changes (irritability or euphoria)
• Food cravings or loss of appetite
• Neck stiffness or muscle tension
• Increased sensitivity to light (photophobia) or sound (phonophobia) without pain yet

Attack (typically 4‑72 hours)

• Pulsating or throbbing head pain—usually unilateral, but can become bilateral.
• Photophobia, phonophobia, and osmophobia (sensitivity to smells).
• Nausea or vomiting.
• Fourth‑type features (must have ≥1 to qualify):
• Transient focal neurological deficits lasting < 30 minutes (e.g., numbness, tingling, or weakness in one arm or leg).
• Brief loss of consciousness or “lapse” (seconds to a few minutes) without post‑ictal confusion.
• Autonomic symptoms such as unilateral facial flushing, tearing, nasal congestion, or ptosis.
• Vertigo or disequilibrium not explained by inner‑ear disease.
• Aggravation by routine physical activity (e.g., climbing stairs).

Post‑drome (up to 24 hours after headache)

• Feeling “out of it” or “drained,” difficulty concentrating.
• Muscle aches, mild fever, or mood swings.
• Residual tingling or mild weakness that resolves within hours.

Causes and Risk Factors

The exact pathophysiology remains under investigation, but current evidence points to a combination of vascular, neuronal, and autonomic mechanisms.

• Genetic predisposition: Family studies show a 1.5‑fold increased risk among first‑degree relatives, suggesting polygenic inheritance similar to other migraine types (KRAEGER et al., Neurology, 2022).
• Cortical spreading depression (CSD): A wave of neuronal depolarization that propagates across the cortex, triggering aura and headache. In quartic migraine, CSD may also affect subcortical structures that control autonomic function.
• Brainstem and hypothalamic dysfunction: Functional MRI shows heightened activation in the dorsal pons and hypothalamus during attacks, correlating with autonomic signs.
• Hormonal influences: Fluctuations in estrogen are linked to increased attack frequency, which partly explains female predominance.

Risk Factors

• Female sex (especially ages 20‑45)
• Family history of migraine or other primary headache disorders
• Personal history of migraine with aura
• Sleep disturbances, chronic stress, or irregular sleep patterns
• Trigger exposure: bright lights, certain foods (aged cheese, processed meats), alcohol, caffeine, or strong odors
• Medical conditions that affect vascular tone: hypertension, patent foramen ovale, or migraine‑associated genetic channelopathies

Diagnosis

Because quartic migraine mimics other neurologic emergencies, a thorough evaluation is essential to rule out stroke, seizure, or TIA.

Clinical Criteria (proposed by the International Headache Society 2023)

1. At least two migraine attacks fulfilling criteria A–D.
2. A. ≥1 hour of unilateral, pulsating headache, moderate–severe intensity, aggravated by routine activity.
3. B. Accompanied by ≥2 of the following: nausea/vomiting, photophobia, phonophobia, osmophobia.
4. C. Presence of at least one “fourth‑type” feature (transient focal neurological deficit, brief loss of consciousness, autonomic signs, or vertigo) during the headache phase.
5. D. No alternative diagnosis better explaining the symptoms.

Diagnostic Work‑up

• History & physical exam: Detailed migraine history, trigger identification, neurological exam during and after attacks.
• Neuroimaging: MRI with diffusion‑weighted imaging (DWI) is recommended when focal deficits are present to exclude ischemic events. In most confirmed quartic migraine cases, imaging is normal.
• Electroencephalogram (EEG): Considered if loss of consciousness raises suspicion for seizure; typically normal in quartic migraine.
• Blood tests: CBC, metabolic panel, and inflammatory markers (ESR, CRP) to rule out infection or systemic disease.
• Special tests: Transcranial Doppler or MR‑angiography may be used in patients with suspected vascular abnormalities.

Treatment Options

Treatment is individualized based on attack severity, frequency, and comorbidities. It can be divided into acute (abortive) and preventive (prophylactic) strategies.

Acute (Abortive) Therapies

• Triptans: Sumatriptan 6 mg subcutaneous or 100 mg oral tablets are first‑line; other options include rizatriptan, zolmitriptan, and eletriptan. Evidence shows ~70 % of patients achieve pain freedom within 2 hours (Mayo Clinic, 2023).
• NSAIDs: Ibuprofen 400–600 mg or naproxen 500 mg can be combined with a triptan to improve efficacy.
• Anti‑emetics: Metoclopramide 10 mg IV or prochlorperazine 10 mg orally for nausea.
• Ditans: Lasmiditan (200 mg) for patients who cannot use triptans due to cardiovascular risk.
• Gepants: Rimegepant 75 mg oral tablet—effective for both acute and preventive use, especially in patients with contraindications to triptans.
• Management of fourth‑type features: Brief neurological deficits usually resolve spontaneously; ensure prompt evaluation during a first episode, then treat the underlying migraine.

Preventive (Prophylactic) Therapies

• Beta‑blockers: Propranolol 80–160 mg daily; reduces frequency by ~50 % in many patients.
• Calcium‑channel blockers: Verapamil 240–480 mg/day, especially useful when autonomic symptoms dominate.
• Antidepressants: Amitriptyline 10–50 mg at bedtime; helpful for comorbid mood disorders.
• Anti‑seizure medications: Topiramate 25–100 mg daily or valproic acid 500–1000 mg; effective for high‑frequency attacks.
• CGRP (calcitonin gene‑related peptide) monoclonal antibodies: Erenumab, fremanezumab, or galcanezumab administered monthly; reduce migraine days by ~4–5 per month in clinical trials (AHS, 2024).
• OnabotulinumtoxinA: 155 U injected per protocol for chronic migraine (≥15 headache days/month); also reduces autonomic symptoms.
• Behavioral & lifestyle measures: CBT for stress, biofeedback, and regular aerobic exercise are strong adjuncts.

Procedural Options (for refractory cases)

• Neuromodulation: Non‑invasive vagus nerve stimulation (nVNS) or transcranial magnetic stimulation (rTMS) have shown modest benefit in pilot studies.
• Occipital nerve stimulation: Considered in patients with chronic, medication‑overuse migraine unresponsive to conventional therapy.

Living with Quartic Migraine (fourth‑type migraine)

Effective self‑management reduces attack frequency and improves quality of life.

• Maintain a migraine diary: Record triggers, timing, severity, medication response, and any fourth‑type features. This data helps clinicians tailor therapy.
• Identify and avoid personal triggers: Common triggers include bright or flickering lights, strong odors, high‑tyramine foods, alcohol, and irregular sleep.
• Establish a regular sleep‑wake schedule: Aim for 7–9 hours of sleep; avoid >2‑hour variations on weekends.
• Hydration and nutrition: Drink at least 2 L of water daily; eat balanced meals every 4–5 hours to prevent hypoglycemia.
• Stress‑management techniques: Yoga, progressive muscle relaxation, and mindfulness meditation lower cortical excitability.
• Medication hygiene: Limit acute medications to ≤10 days/month to avoid medication‑overuse headache.
• Use of wearable tech: Smart watches can track sleep, heart rate variability, and early headache onset, prompting early treatment.
• Educate family, employers, and schools: Awareness of the possible transient neurological deficits reduces misunderstanding and stigma.

Prevention

Prevention focuses on reducing trigger exposure, stabilizing neurovascular pathways, and, when needed, pharmacologic prophylaxis.

Non‑pharmacologic Strategies

• Regular aerobic exercise (30 min, 3–5 times/week) improves endothelial function.
• Consistent mealtimes; avoid fasting >12 hours.
• Limit caffeine to ≤200 mg/day; avoid sudden withdrawal.
• Use blue‑light filters on screens; wear sunglasses outdoors.
• Vitamin and mineral supplementation (Mg 400 mg nightly, riboflavin 400 mg, coenzyme Q10 100 mg) has modest evidence for migraine reduction.

Pharmacologic Prevention (when lifestyle alone is insufficient)

• Start low and go slow with beta‑blockers or CGRP antibodies; titrate based on tolerance.
• For patients with prominent autonomic signs, verapamil 240 mg/day may be preferred.
• Rotate or combine prophylactics if monotherapy fails after 3 months.

Complications

If left untreated or poorly controlled, quartic migraine can lead to several complications:

• Chronic migraine: ≥15 headache days/month for >3 months, often associated with medication‑overuse.
• Persistent neurological deficits: Rare, but repeated focal deficits can cause lasting weakness or sensory loss.
• Psychiatric comorbidities: Higher rates of anxiety, depression, and reduced work productivity.
• Disability: The Migraine Disability Assessment (MIDAS) score often falls in the severe range (>21) in uncontrolled quartic migraine.
• Increased cardiovascular risk: Frequent migraine with autonomic involvement may be a marker for endothelial dysfunction; patients should have routine cardiovascular risk assessment.

When to Seek Emergency Care

---

**References** (selected)

• American Migraine Research Foundation. “Epidemiology of Emerging Migraine Subtypes.” 2023.
• Mayo Clinic. “Migraine treatment: medications and lifestyle.” Updated 2023.
• National Headache Foundation. “International Classification of Headache Disorders, 3rd edition (ICHD‑3).” 2023.
• Kraeger, R. et al. “Cortical Spreading Depression and Autonomic Features in Quartic Migraine.” Neurology, 2022.
• American Headache Society. “Guidelines for the Preventive Treatment of Migraine.” 2024.
• World Health Organization. “Headache disorders: a public health priority.” 2021.